SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor
12 Apr 2023 //
PR NEWSWIRE
SciNeuro Pharma Announces the Appointment of Guojun Bu, Ph.D., as CSO
02 Dec 2022 //
PRNEWSWIRE
SciNeuro Pharma Announces License and Option Agreement with GSK for CNS Diseases
01 Jun 2022 //
PRNEWSWIRE
SciNeuro and Mabylon Collaborate to develop therapy for Neurological Diseases
26 Oct 2021 //
BUSINESSWIRE